128 related articles for article (PubMed ID: 32748963)
1. Rapid establishment of a COVID-19 convalescent plasma program in a regional health care delivery network.
Blackall D; Wulff S; Roettger T; Jacobs L; Lacasse A; Patri M; Zinser P; Pherez F; Jamkhana Z; Frey SE; Smith L; Goel R; Katz L
Transfusion; 2020 Oct; 60(10):2203-2209. PubMed ID: 32748963
[TBL] [Abstract][Full Text] [Related]
2. Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion.
Wirz OF; Röltgen K; Stevens BA; Pandey S; Sahoo MK; Tolentino L; Verghese M; Nguyen K; Hunter M; Snow TT; Singh AR; Blish CA; Cochran JR; Zehnder JL; Nadeau KC; Pinsky BA; Pham TD; Boyd SD
Front Immunol; 2021; 12():739037. PubMed ID: 34594341
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China.
Li L; Yang R; Wang J; Lv Q; Ren M; Zhao L; Chen H; Xu H; Xie S; Xie J; Lin H; Li W; Fang P; Gong L; Wang L; Wu Y; Liu Z
Transfusion; 2020 Aug; 60(8):1773-1777. PubMed ID: 32491199
[TBL] [Abstract][Full Text] [Related]
4. Screening donors for COVID-19 convalescent plasma.
Wang HE; Ostrosky-Zeichner L; Katz J; Wanger A; Bai Y; Sridhar S; Patel B
Transfusion; 2021 Apr; 61(4):1047-1052. PubMed ID: 33368395
[TBL] [Abstract][Full Text] [Related]
5. Rapid development of a de novo convalescent plasma program in response to a global pandemic: A large southeastern U.S. blood center's experience.
Reik R; Gammon RR; Carol N; Smith J; Grable M; Forbes S; Wu Y; Reed L; Rogers M; Prichard A; Paul S; Scholl G
J Clin Apher; 2021 Aug; 36(4):533-546. PubMed ID: 33648025
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 convalescent plasma donor characteristics, product disposition, and comparison with standard apheresis donors.
Lasky B; Goodhue Meyer E; Steele WR; Crowder LA; Young PP
Transfusion; 2021 May; 61(5):1471-1478. PubMed ID: 33458811
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 convalescent plasma cohort study: Evaluation of the association between both donor and recipient neutralizing antibody titers and patient outcomes.
Yokoyama APH; Wendel S; Bonet-Bub C; Fachini RM; Dametto APF; Blumm F; Dutra VF; Candelaria GTP; Sakashita AM; Machado RRG; Fontão-Wendel R; Hamerschlak N; Achkar R; Assunção MSC; Scuracchio P; Nudelman V; Pastore L; Pinho JRR; Ben MD; Filho RK; Marra AR; Amano MT; Kallás EG; Helito AS; de Carvalho CRR; Araujo DB; Durigon EL; Camargo AA; Rizzo LV; Reis LFL; Kutner JM
Transfusion; 2021 Aug; 61(8):2295-2306. PubMed ID: 34173248
[TBL] [Abstract][Full Text] [Related]
8. Rapid and Successful Implementation of a COVID-19 Convalescent Plasma Programme-The South African Experience.
Glatt TN; Hilton C; Nyoni C; Swarts A; Swanevelder R; Cowley J; Mmenu C; Moyo-Gwete T; Moore PL; Kutama M; Jaza J; Phayane I; Brits T; Koekemoer J; Jentsch U; Nelson D; van den Berg K; Vermeulen M
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696480
[TBL] [Abstract][Full Text] [Related]
9. Deterrents in recruitment of COVID-19 convalescent plasma donors: Experience from a hospital-based blood centre in India.
Dhiman Y; Coshic P; Pandey HC; Khatiwada B; Singh J; Mehta V; Gupta S
Transfus Med; 2021 Jun; 31(3):149-154. PubMed ID: 33749020
[TBL] [Abstract][Full Text] [Related]
10. How we secured a COVID-19 convalescent plasma procurement scheme in Japan.
Terada M; Kutsuna S; Togano T; Saito S; Kinoshita N; Shimanishi Y; Suzuki T; Miyazato Y; Inada M; Nakamoto T; Nomoto H; Ide S; Sato M; Maeda K; Matsunaga A; Satake M; Matsubayashi K; Tsuno H; Kojima M; Kuramistu M; Tezuka K; Ikebe E; Okuma K; Hamaguchi I; Shiratori K; Sato M; Kawakami Y; Inaba K; Igarashi S; Yamauchi R; Matsumura M; Ishimaru K; Zhang B; Kuge C; Ishihara M; Gouda M; Tanaka K; Ishizaka Y; Ohmagari N
Transfusion; 2021 Jul; 61(7):1998-2007. PubMed ID: 34096059
[TBL] [Abstract][Full Text] [Related]
11. Hospital-Based Donor Recruitment and Predonation Serologic Testing for COVID-19 Convalescent Plasma.
Balcerek J; Trejo E; Levine K; Couey P; Kornberg ZV; Rogine C; Young C; Li PJ; Shy BR; Taylor JE; Bakhtary S; Friedlander T; Lynch KL; Bern C; Esensten JH
Am J Clin Pathol; 2021 Mar; 155(4):515-521. PubMed ID: 33399201
[TBL] [Abstract][Full Text] [Related]
12. Provision of COVID-19 Convalescent Plasma in a Resource-Constrained State.
Ipe TS; Le T; Quinn B; Kellar S; Clark M; Carlisle S; Rassmann A; Hennigan S; Ridenour T; Roberts A; Avery D; Ryan S; Pearson S; Kothari A; Patil N
Transfusion; 2020 Dec; 60(12):2828-2833. PubMed ID: 32989778
[TBL] [Abstract][Full Text] [Related]
13. Factors driving availability of COVID-19 convalescent plasma: Insights from a demand, production, and supply model.
Russell WA; Grebe E; Custer B
Transfusion; 2021 May; 61(5):1370-1376. PubMed ID: 33590906
[TBL] [Abstract][Full Text] [Related]
14. Blood group O convalescent plasma donations have significantly lower levels of SARS-CoV-2 IgG antibodies compared to blood group A donations.
Hayes C; Rubenstein W; Gibb D; Klapper E; Tanaka J; Pepkowitz S
Transfusion; 2021 Aug; 61(8):2245-2249. PubMed ID: 34036595
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda.
Muttamba W; Lusiba J; Namakula LO; Byakika-Kibwika P; Ssali F; Ddungu H; Mugenyi L; Kiwanuka N; Sekibira R; Kityo C; Keyune D; Acana S; Musinguzi A; Masasi A; Byamugisha J; Mpanju D; Musoki WJ; Tukamuhebwa HA; Nakwagala F; Bagaya BS; Kayongo A; Kimuli I; Nantanda R; Katagira W; Buregyeya E; Byanyima R; Byarugaba B; Siddharthan T; Mwebesa H; Charles O; Joloba ML; Bazeyo W; Kirenga B
PLoS One; 2021; 16(6):e0252306. PubMed ID: 34138909
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 antibody changes in patients receiving COVID-19 convalescent plasma from normal and vaccinated donors.
Leon J; Merrill AE; Rogers K; Kurt J; Dempewolf S; Ehlers A; Jackson JB; Knudson CM
Transfus Apher Sci; 2022 Apr; 61(2):103326. PubMed ID: 34862140
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of coronavirus disease 19 convalescent plasma donors and donations in the New York metropolitan area.
Jain S; Garg K; Tran SM; Rask IL; Tarczon M; Nandi V; Kessler DA; Strauss D; Sachais BS; Yazdanbakhsh K; Rehmani S; Luchsinger L; Shi PA
Transfusion; 2021 Aug; 61(8):2374-2383. PubMed ID: 33904609
[TBL] [Abstract][Full Text] [Related]
18. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
Trials; 2021 May; 22(1):342. PubMed ID: 34001174
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
[TBL] [Abstract][Full Text] [Related]
20. Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income countries.
Bloch EM; Goel R; Wendel S; Burnouf T; Al-Riyami AZ; Ang AL; DeAngelis V; Dumont LJ; Land K; Lee CK; Oreh A; Patidar G; Spitalnik SL; Vermeulen M; Hindawi S; Van den Berg K; Tiberghien P; Vrielink H; Young P; Devine D; So-Osman C
Vox Sang; 2021 Jan; 116(1):18-35. PubMed ID: 32533868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
